| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Dr. Enting), University Hospital, Groningen, The Netherlands; and Department of Neurology (Drs. Demopoulos, DeAngelis, and Abrey), Memorial Sloan-Kettering Cancer Center, New York, NY.
Address correspondence and reprint requests to Dr. Lauren E. Abrey, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; e-mail: abreyl{at}mskcc.org
The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.
Received March 10, 2004. Accepted in final form May 5, 2004.
Dr. Abrey has received grant funding in excess of $10,000 each from Genentech, Inc. and Schering-Plough Research Institute.
This article has been cited by other articles:
|
|
 |
|
  M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan Primary CNS Lymphoma in Immunocompetent Patients Oncologist, May 1, 2009; 14(5): 526 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Boehme, N. Schmitz, S. Zeynalova, M. Loeffler, and M. Pfreundschuh CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Blood, April 23, 2009; 113(17): 3896 - 3902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Schlegel Review: Primary CNS lymphoma Therapeutic Advances in Neurological Disorders, March 1, 2009; 2(2): 93 - 104. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, R. D. Brown, D. F. Kraemer, C. Soussain, and E. A. Neuwelt Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma Neuro-oncol, January 1, 2009; 11(5): 503 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Soussain, K. Hoang-Xuan, L. Taillandier, E. Fourme, S. Choquet, F. Witz, O. Casasnovas, B. Dupriez, B. Souleau, A.-L. Taksin, et al. Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire J. Clin. Oncol., May 20, 2008; 26(15): 2512 - 2518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Yamanaka, K. Morii, Y. Shinbo, J. Homma, M. Sano, N. Tsuchiya, N. Yajima, T. Tamura, H. Hondoh, H. Takahashi, et al. Results of Treatment of 112 Cases of Primary CNS Lymphoma Jpn. J. Clin. Oncol., May 1, 2008; 38(5): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Muldoon, C. Soussain, K. Jahnke, C. Johanson, T. Siegal, Q. R. Smith, W. A. Hall, K. Hynynen, P. D. Senter, D. M. Peereboom, et al. Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check J. Clin. Oncol., June 1, 2007; 25(16): 2295 - 2305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Soussain, L. L. Muldoon, C. Varallyay, K. Jahnke, L. DePaula, and E. A. Neuwelt Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma Clin. Cancer Res., April 15, 2007; 13(8): 2504 - 2511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Fischer, E. Thiel, H.-A. Klasen, J. Birkmann, K. Jahnke, P. Martus, and A. Korfel Prospective trial on topotecan salvage therapy in primary CNS lymphoma Ann. Onc., July 1, 2006; 17(7): 1141 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Batchelor and J. S. Loeffler Primary CNS Lymphoma J. Clin. Oncol., March 10, 2006; 24(8): 1281 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. DeAngelis and F. M. Iwamoto An Update on Therapy of Primary Central Nervous System Lymphoma Hematology, January 1, 2006; 2006(1): 311 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Wong Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities Clin. Cancer Res., October 1, 2005; 11(19): 7151s - 7157s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Wong, L. E. Abrey, R. H. Enting, A. Demopoulos, and L. M. DeAngelis Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide Neurology, March 8, 2005; 64(5): 934 - 934. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
